Advanced Search

Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2008 April;49(2) > The Journal of Cardiovascular Surgery 2008 April;49(2):159-65

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

 

The Journal of Cardiovascular Surgery 2008 April;49(2):159-65

LOWER LIMB ISCHEMIA 

 REVIEWS

Present and future of endovascular SFA treatment: stents, stent-grafts, drug coated balloons and drug coated stents

Bosiers M. 1, Deloose K. 1, Verbist J. 1, Peeters P. 2

1 Department of Vascular Surgery AZ St-Blasius, Dendermonde, Belgium
2 Department of Cardiovascular and Thoracic Surgery Imelda Hospital, Bonheiden, Belgium

The current evolution towards treating more complex femoropopliteal lesions as seen in the renewed TASC II recommendations clearly reflects the continuous evolutions in femoropopliteal stent design. Recent stent design improvements focus on decreasing stent fractures rates which can negatively impact patency rates. By rearranging strut alignment towards helical connecting bridges or full helical stent designs, stent designers have successfully improved the fracture resistance of their stents. The superior fracture resistance of the latest stent generation in combination with the production of long nitinol stents of up to 20 cm in length allow that more difficult and complex lesions can be treated endovascularly. The continuous perfection of nitinol stent platforms followed by the transfer of coronary technologies (e.g. active coatings) towards peripheral devices might broaden the indications for the minimal invasive strategy towards TransAtlantic Inter-Society Consensus (TASC) II C&D lesions.

language: English


FULL TEXT  REPRINTS

top of page